Search Results - multiple+myeloma

7 Results

Sort By:

Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex

Abstract: The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure....

Published: 7/3/2024 | Inventor(s): John (Jay) Schneekloth, Kenneth Felsenstein, John Simmons, Lindsey Saunders, Beverly Mock, Peter Gareiss, David Calabrese, Elena Leon

Keywords(s): C-MYC, G-Quadruplex (G4), MULTIPLE MYELOMA, Schneekloth

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Synthetic lipopeptide inhibitors of RAS oncoproteins

Abstract: It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the...

Published: 6/11/2024 | Inventor(s): Nadya Tarasova, Sergey Tarasov, Vadim Gaponenko, Joseph Kates, Michael Dean, Alla Ivanova

Keywords(s): COLON, LUNG, MULTIPLE MYELOMA, Pancreatic Cancer, RAS, THYROID CANCER

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)

Abstract: Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam, Benjamin Buelow

Keywords(s): act, adoptive cell therapy, B-cell Malignancies, B-cell Maturation Antigen, BCMA, BIOLOGIC, CANCER, CAR, chimeric antigen receptor, Hodgkin Lymphoma, Hodgkin’s Lymphoma, Kochenderfer, Mm, MULTIPLE MYELOMA, Non-Hodgkin Lymphoma, Non-Hodgkin’s Lymphoma, Plasma Cell Malignancies

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Therapeutic antibody-drug conjugates targeting CD56-positive cancers

Abstract: The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions. It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Yang Feng, Zhongyu Zhu, John Maris, Robyn Sussman

Keywords(s): ADC, GLYCOPROTEIN, MULTIPLE MYELOMA, Neuroblastoma, pyrrolobenzodiazepine, small-cell lung cancer

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity

Abstract: Recombinant immunotoxins (RITs) constitute a promising solution to hematologic cancers (e.g., Multiple Myeloma [MM]). RITs are chimeric proteins composed of a targeting domain fused to a bacterial toxin. Upon binding to a cancer cell displaying the target antigen, RITs are internalized, metabolized and the released toxin kills the cell. While...

Published: 5/21/2024 | Inventor(s): Ira Pastan

Keywords(s): Abd, Albumin Binding Domain, antibody conjugate, B-cell Maturation Antigen, BCMA, Hematologic Cancer, Mm, MULTIPLE MYELOMA, Pastan, Recombinant Immunotoxin, Rit

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases

This technology relates to novel animal models of several human bone diseases that have been linked to enhanced BMP signaling. More specifically, this mouse model expresses a mutant receptor for BMP, known as Alk2 that is always actively signaling. This receptor is under the control of the Cre-loxP system, which allows control of expression of the...

Published: 7/25/2024 | Inventor(s): Manas Ray, Gregory Scott, Yuji Mishina

Keywords(s): BAXXXX, BMP:, Bone, Craniosynostosis, Disease, Enhanced, Expressing, Fibrodysplasia ossificans progressiva, Human, IDXXXX, IXXXXX, Model, MORPHOGENETIC, Mouse, MULTIPLE MYELOMA, Protein, SIGNALING

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, ResearchProducts > Animal Models, Application > Diagnostics, Application > Research Materials

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology